| Management target | EBITDA Year 2 |
|---|
| Revenue growth | 9% YoY growth in Q1 FY27. |
|---|---|
| Margins | EBITDA margin expanded 241 bps YoY to 23.2%. |
| Demand visibility | Strong, driven by higher MR productivity and key brand strength. |
| Management confidence | High; citing sustained traction and disciplined capital allocation. |
Growth
Q1FY27 Revenue reached ₹822 Mn (+8.8% YoY); Operating EBITDA rose to ₹191 Mn (+21.4% YoY) with margins at 23.2%.
Outlook
Targeting ~₹100 Mn EBITDA from Aequitas by Year 2; focuses on sustaining profitable growth through hospital channel expansion.
Risks
Potential macro-economic shifts, regulatory trends, and competitive pressures within the pharmaceutical industry.
Last quarter's promises, checked
Delivered
- Guided double-digit growth → delivered 14.2% in Q4 (= BEAT)
- Guided 1.5x IPM growth → delivered 1.35x (14.2% vs 10.5% IPM) (= BEAT)
- Guided 9-10 new launches/SKUs for FY26 → delivered 9 (6 products + 3 SKUs) (= BEAT)
Partly delivered
- Guided FY26 revenue growth 12-14% → delivered 7% (= MISS)
Investor Presentation filed with NSE, NSE: JAGSNPHARM. Summary written with AI assistance from the document.
Jagsonpal Pharmaceuticals Ltd: key numbers
- Share price
- ₹242.29
- Market cap
- ₹1,598 Cr
- Revenue (annual)
- ₹287.2 Cr
- Net profit (annual)
- ₹43.08 Cr
- P/E (TTM)
- 35.1×Sector 50.4×
- Promoter holding
- 69.05%+1.16% QoQ
- FII holding
- 2.30%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Jagsonpal Pharmaceuticals Ltd
All →Jagsonpal Pharmaceuticals Acquisition Worth ₹46.7 Cr
Jagsonpal Pharmaceuticals Ltd will acquire the Wellness Portfolio of Group Pharmaceuticals Ltd. The transaction involves a total consideration capped at ₹46.7 Crore.
- Value
- ₹46.70 Cr
Jagsonpal Pharmaceuticals Annual General Meeting
Jagsonpal Pharmaceuticals held its 47th Annual General Meeting on September 18, 2026. Shareholders transacted business including adoption of financial statements and director appointments.
Jagsonpal Pharmaceuticals Earnings Call Transcript: Key Takeaways
Jagsonpal reported a strong Q1FY27 with 9% revenue growth and 22% PAT growth, outperforming industry rates. The focus is on higher-margin specialty segments and integrating the Equitas acquisition to enter the hospital channel.
- Call
- Guides 18% growth
Jagsonpal Pharmaceuticals Q1 FY27 Results: Net Profit ₹13.2 Cr, Up 22.2% YoY
Jagsonpal Pharmaceuticals Ltd reported revenue from operations of ₹82.2 Cr (+8.7% YoY) and net profit of ₹13.2 Cr (+22.2% YoY) for Q1 FY27.
- Key figure
- Net profit ₹13.2 Cr · +22.2% YoY
Jagsonpal Pharmaceuticals Earnings Call: Key Takeaways
Jagsonpal reported Q4 revenue of ₹64cr (up 10% YoY) and FY26 revenue of ₹287cr (up 7%). Strategy focuses on MR productivity and portfolio rejuvenation in Gynaecology and Dermatology.
Jagsonpal Pharmaceuticals Earnings Call: Key Takeaways
Jagsonpal Pharmaceuticals reported strong FY26 results with 7% revenue growth and 19% PAT growth. Strategy focuses on an asset-light model, high-margin Rx brands, and shareholder returns via buybacks and dividends.